Cracking The Code: Understanding Analyst Reviews For XOMA

XOMA Corporation +0.11% Pre

XOMA Corporation





0.00% Pre

4 analysts have expressed a variety of opinions on XOMA (NASDAQ:XOMA) over the past quarter, offering a diverse set of opinions from bullish to bearish.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 3 1 0 0 0
Last 30D 0 1 0 0 0
1M Ago 1 0 0 0 0
2M Ago 1 0 0 0 0
3M Ago 1 0 0 0 0

Analysts have recently evaluated XOMA and provided 12-month price targets. The average target is $65.5, accompanied by a high estimate of $74.00 and a low estimate of $40.00. This current average represents a 11.49% decrease from the previous average price target of $74.00.

price target chart

Exploring Analyst Ratings: An In-Depth Overview

The perception of XOMA by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Jason Zhuang Leerink Partners Announces Outperform $40.00 -
Joseph Pantginis HC Wainwright & Co. Maintains Buy $74.00 -
Joseph Pantginis HC Wainwright & Co. Maintains Buy $74.00 $74.00
Joseph Pantginis HC Wainwright & Co. Maintains Buy $74.00 -

Key Insights:

  • Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to XOMA. This information provides a snapshot of how analysts perceive the current state of the company.
  • Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of XOMA compared to the broader market.
  • Price Targets: Analysts provide insights into price targets, offering estimates for the future value of XOMA's stock. This comparison reveals trends in analysts' expectations over time.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of XOMA's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on XOMA analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Unveiling the Story Behind XOMA

XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

Financial Insights: XOMA

Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: XOMA displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 23.35%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: XOMA's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1171.69% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -22.07%, the company may need to address challenges in generating satisfactory returns for shareholders.

Return on Assets (ROA): XOMA's ROA stands out, surpassing industry averages. With an impressive ROA of -11.99%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: XOMA's debt-to-equity ratio surpasses industry norms, standing at 1.4. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

The Basics of Analyst Ratings

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via